Drug Profile
Research programme: FASN inhibitors - Sagimet Biosciences
Alternative Names: TVB-3664Latest Information Update: 23 May 2022
Price :
$50
*
At a glance
- Originator 3-V Biosciences
- Developer Sagimet Biosciences
- Class Antineoplastics; Antivirals; Hepatoprotectants; Small molecules
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neuroendocrine tumours
- No development reported Cytomegalovirus infections; Hepatitis C; Herpes simplex virus infections; Non-alcoholic steatohepatitis; Parainfluenza virus infections; Respiratory syncytial virus infections; Solid tumours
Most Recent Events
- 08 Apr 2022 Preclinical trials in Neuroendocrine tumours in USA (PO)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Neuroendocrine tumours presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 28 Nov 2021 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (PO)